Cargando…

The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial

BACKGROUND: In a Phase II clinical trial, we reported the effectiveness and safety of a sandwich neoadjuvant treatment based on a modified oxaliplatin plus capecitabine (XELOX) regimen for locally advanced rectal cancer (LARC). The pathologic complete response (pCR) rate was 42.2%, and no patient pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yong-Hong, Wei, Jia-Wang, Chang, Hui, Xiao, Wei-Wei, Lin, Jun-Zhong, Cai, Mu-Yan, Cai, Pei-Qiang, Kong, Ling-Heng, Chen, Gong, Pan, Zhi-Zhong, Zeng, Zhi-Fan, Ding, Pei-Rong, Gao, Yuan-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188179/ https://www.ncbi.nlm.nih.gov/pubmed/30349369 http://dx.doi.org/10.2147/CMAR.S168573

Ejemplares similares

The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Liu, Guo-Chen, et al.
Publicado: (2015)

Tumor deposits: markers of poor prognosis in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy
por: Zhang, Lu-Ning, et al.
Publicado: (2015)

Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer
por: Fan, Wen-Hua, et al.
Publicado: (2017)

Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study
por: Sheng, Xue-Qing, et al.
Publicado: (2022)

The value of forceps biopsy and core needle biopsy in prediction of pathologic complete remission in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
por: Tang, Jing-Hua, et al.
Publicado: (2015)

Monitoring neoadjuvant therapy responses in rectal cancer using multimodal nonlinear optical microscopy
por: Li, Lian-Huang, et al.
Publicado: (2017)

Local environment in biopsy better predict the pathological response to neoadjuvant chemoradiotherapy in rectal cancer
por: Huang, Yan, et al.
Publicado: (2019)

Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study
por: Yu, Xin, et al.
Publicado: (2018)

Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open‐label, multicenter, single‐arm, phase 2 trial
por: Liu, Shuang, et al.
Publicado: (2023)

Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis
por: Liu, Guo-Chen, et al.
Publicado: (2016)

Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer
por: Zhang, Shu, et al.
Publicado: (2021)

The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer
por: Biswas, Tithi, et al.
Publicado: (2017)

Impact of interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients
por: Mei, Shi-Wen, et al.
Publicado: (2020)

The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy
por: Wang, Qiao-xuan, et al.
Publicado: (2021)

The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy
por: Zhang, Lu-Ning, et al.
Publicado: (2015)

Adjuvant chemotherapy for rectal cancer with complete pathological response (pCR) may not be necessary: a pooled analysis of 5491 patients
por: Hu, Xiang, et al.
Publicado: (2019)

High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer
por: Wang, Qiao-Xuan, et al.
Publicado: (2022)

Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer
por: Chen, Jia-Nan, et al.
Publicado: (2020)

Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0
por: You, Kai-yun, et al.
Publicado: (2014)

Impact factors of lymph node retrieval on survival in locally advanced rectal cancer with neoadjuvant therapy
por: Mei, Shi-Wen, et al.
Publicado: (2020)

Identification of Locally Advanced Rectal Cancer with Low Risk of Local Recurrence
por: Wang, Qiao-Xuan, et al.
Publicado: (2015)

Comparing neoadjuvant long-course chemoradiotherapy with short-course radiotherapy in rectal cancer
por: Wang, Jian, et al.
Publicado: (2021)

Neoadjuvant chemotherapy without radiation as a potential alternative treatment for locally advanced rectal cancer: A meta-analysis
por: Wu, Pei, et al.
Publicado: (2021)

Pretreatment TACC3 expression in locally advanced rectal cancer decreases the response to neoadjuvant chemoradiotherapy
por: Ma, Wen-juan, et al.
Publicado: (2018)

Neoadjuvant treatments for resectable rectal cancer: A network meta-analysis
por: Zhong, Wei, et al.
Publicado: (2020)

Primary pulmonary lymphoepithelioma-like carcinoma: A case report of pathological complete response (pCR) by neoadjuvant treatment
por: Zhang, Liqin, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial
por: Mei, Wei-Jian, et al.
Publicado: (2023)

Prognostic Value of the Cycle Number of Perioperative Chemotherapy in Locoregionally Advanced Rectal Cancer: a Propensity Score Matching Analysis
por: Chang, Hui, et al.
Publicado: (2018)

Radiotherapy for stage IIA rectal cancer may not benefit all
por: Hu, Xiang, et al.
Publicado: (2017)

Pathological Assessment of the AJCC Tumor Regression Grading System After Preoperative Chemoradiotherapy for Chinese Locally Advanced Rectal Cancer
por: Zhang, Lu-Ning, et al.
Publicado: (2016)

Value of transrectal ultrasonography for tumor node metastasis restaging in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy
por: Peng, Hai-Hua, et al.
Publicado: (2013)

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Lin, Huaqin, et al.
Publicado: (2021)

Elevated CA19-9 as the Most Significant Prognostic Factor in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy
por: Zhang, Lu-Ning, et al.
Publicado: (2015)

Higher nuclear EGFR expression is a better predictor of survival in rectal cancer patients following neoadjuvant chemoradiotherapy than cytoplasmic EGFR expression
por: Yang, Ching-Chieh, et al.
Publicado: (2019)

Experimental Assessment of Thermal Performance and Bridging Effects of Low-Cost Sandwich Panels under a High-Temperature Impinging Jet
por: Ye, Wei, et al.
Publicado: (2020)

Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer
por: Zeng, Wei-Gen, et al.
Publicado: (2015)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

A 41-Gene Pair Signature for Predicting the Pathological Response of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiation
por: Xue, Zhengfa, et al.
Publicado: (2021)

Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: Oxaliplatin in neoadjuvant treatment for rectal cancer
por: De Felice, Francesca, et al.
Publicado: (2017)

Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy
por: Guo, Su-ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j1msfm0jmv8b4158n2rd3ap7ln